Clinical Trial Update: Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial is evaluating intravenous efgartigimod in children with generalized myasthenia gravis. The study focuses on pharmacokinetics, pharmacodynamics…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Generalized Myasthenia Gravis | Phase 2, Phase 3 | Status: RECRUITING